Parker Waichman LLP Headlines by Topic
Natrecor
Feds Join Lawsuit Alleging Natrecor was Illegally Marketed
Feb 20, 2009
| Parker Waichman LLP
The United States Justice Department (DOJ) just announced that it is joining in two whistleblower lawsuits against drug maker Scios Inc. and Johnson...
Natrecor a Drag on Johnson & Johnson since Reports of Kidney Failure, Deaths
Dec 6, 2007
| Parker Waichman LLP
Natrecor side effect reports have taken a toll on the finances of Johnson & Johnson. Natrecor was considered a potential hit in 2001 when...
Off-label drug marketing: Missing the mark
Oct 22, 2006
| Mercury News
The heart-failure drug Natrecor seemed sure to become a blockbuster after Scios of Fremont put it on the market in 2001. Besides its use in...
Scios to Conduct Safety Study of Natrecor
Jun 1, 2006
| AP
Scios Inc. announced on Thursday that it would spend more than $100 million to conduct a safety and effectiveness study of its controversial heart...
Heart failure drug maker relays new deaths
Jan 3, 2006
| AP
The manufacturer of the heart failure drug Natrecor reported two additional deaths in patients involved in a study carried out three years ago but...
A Growing Clamor over J&J's Natrecor
Oct 6, 2005
| Business Week Europe
The furor over Johnson & Johnson (NYSE: JNJ - news) 's (JNJ) controversial heart failure drug Natrecor shows no signs of abating. In a letter in...
How Johnson & Johnson’s Strategy to Turn Natrecor into a Blockbuster Failed
Aug 25, 2005
| www.Newsinferno.com
In the world of pharmaceuticals, a “blockbuster” is the term reserved for a prescription drug which has annual sales in the...
Scios Heart Drug Curbed
Aug 6, 2005
| San Francisco Chronicle
Fremont biotechnology firm Scios Inc. is taking the first of a series of steps to curb prescribing of its heart drug Natrecor for uses not approved...
Cardiologist: Stop Marketing of Heart Drug
Jul 14, 2005
| Boston Globe
The government should halt sales of the congestive heart failure drug Natrecor until a large study proves it significantly benefits fragile patients,...
Nesiritide — Not Verified
Jul 14, 2005
| New England Journal of Medicine
How can a drug that is associated with higher rates of both renal dysfunction and death than placebo and that costs 50 times as much as standard...
